Fibre determination is in particular important for the analysis of animal feed. Therefore it reproduces the steps of the digestive process in an animal’s stomach. A new method makes dissolving and filtering the components significantly easier and ensures more reliable, reproducible analysis results.

Absolute Antibody has collaborted with the Technical University of Denmark to produce engineered recombinant antibodies for animal toxins. The antibodies are expected to assist sceintists around the globe to carry out snakebite research and diagnostics.

Orgenesis has entered into an agreement with the John Hopkins University under which the institue will make use of Orgenesis’ point-of-care (Pocare) platform to devlop and supply a wide range of cell and gene therapies and technologies.

Researchers from Unige and the University of Manchester have discovered structures based on two-dimensional materials that emit tailor-made light in any colour one could wish for.

Under the European Union’s Horizon 2020 research and innovation programme, the Vamos project has received a mammoth funding. The project aims at developing second-generation sugars from household waste and will be used to produce numerous bio-based products for non-food applications.

Fifteen months after the successful landing of the Nasa Insight mission on Mars, first scientific analyses of ETH Zurich researchers and their partners reveal that the planet is seismically active. The recorded data enables to better constrain the interior of Mars, the primary goal of the Insight mission.

Ingenza announced that the company has reached a technical milestone with Syngenta in their collaboration to develop efficient manufacturing technologies for crop protection products.

Researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences have developed a metasurface which is a new tool to study novel aspects of light.

With an aim to protect patients detected with Covid-19 from all over the world, Pfizer and Biontech have entered into a letter of intent to create a potential vaccine for Coronavirus. Under the terms of the agreement, BNT162 – Biontech’s Covid-19 mrna vaccine programme will be fast-tracked and will enter clinical testing towards the end of April 2020.

Testing of the potential covid-19 vaccine – mrna-1273 developed by the National Institutes of Health and biotechnology firm Moderna has started in the USA. If the research proves successful, the company will be able to mass produce the cure only after 12 to 18 months.